In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.
On Friday October 7 at 2 PM EST, Jan De Backer CEO of Fluidda, will present at the RESCON-summit in New York.
The presentation is entitled: “In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.” And comprises the following topics:
- How can FRI help in cost reduction of the development of (generic) drugs?
- Recent advances in in-silico and in-vitro measurements. (e.g., patient specific CFD models)
For more information on these topics, visit www.fluidda.com or send an email to firstname.lastname@example.org
Categorised in: Miscellaneous / October 6, 2022 3:10 pm /Tags: FRI, Presentation, RESCON